Reinach, Switzerland – (Sep 16th, 2020) – Evolva is pleased to announce that the findings on pain perception, menopausal symptoms, and overall well-being in postmenopausal women from the RESHAW (Resveratrol Supporting Healthy Aging in Women) clinical study have been peer-reviewed and published in The Journal of The North American Menopause Society. The report, “Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women” is the final publication from the extensive two-year RESHAW clinical trial following daily Veri-te™ resveratrol supplementation.

In the crossover comparison, participants completed six questionnaires that
assessed their perceptions on general well-being, that is, pain, mood and depressive symptoms, menopausal symptoms, sleep quality, and quality of life at baseline, and at the 12 and 24 month intervals. Dr. Wong, NHMRC-ARC Dementia Research Fellow, commented that “resveratrol supplementation can reduce chronic pain in age-related osteoarthritis and improve menopause-related quality of life in postmenopausal women.” Furthermore, Dr. Wong adds that “the two-year crossover comparison of regular resveratrol supplementation compared to the placebo, significantly reduced the composite pain score by 18%.”

“Within the same study, we observed reductions in vasomotor symptoms (hot flushes, night sweats) and other somatic symptoms (heart discomfort, sleep problems, muscle, and joint discomfort) with resveratrol supplementation,” states Ms. Thaung Zaw. Professor Peter Howe adds, “although the cause of vasomotor systems is not completely understood, it is postulated that declining estrogen levels may be a factor,” adding that “supplementation with resveratrol, a phytoestrogen with circulatory benefits, may improve aspects of well-being including chronic pain and reduce vasomotor symptoms.”

“The range of significant health benefits from resveratrol supplementation demonstrated in the RESHAW study are a game-changer for women suffering from symptoms related to postmenopause,” states Clare Panchoo, VP, Health Ingredients, Evolva. “The outcomes of the RESHAW study are of great importance with some outstanding conclusions such as a 33% improvement in overall cognitive performance, a reduction in the 10-year probability of major and hip fracture, and now the extremely encouraging outcomes on overall well-being and sleep quality,” adds Panchoo. “These positive findings prove that there is an immediate need for products to be developed following the investigated dosage of 75 mg of Veri-te™ resveratrol twice daily, that can fill the market gap for this much-needed product development to support women’s health,” said Panchoo.

Conducted in Australia by PhD candidate Jay Jay Thaung Zaw, Emeritus Professor Peter Howe, and Dr. Rachel Wong at the University of Newcastle’s Clinical Nutrition Research Centre, Australia, RESHAW is the largest, longest-running study of its kind with resveratrol. The first three peer-reviewed publications from the RESHAW study have reported the cerebrovascular and cognitive benefits, as well as bone mineral density improvements in 125 postmenopausal women.